NEW YORK (GenomeWeb News) – Investment bank Credit Suisse today upgraded Illumina's stock, citing the firm's improved financial performance over the past two quarters and the potential of its tools for the clinical market in the longer term.

Analyst Vamil Divan upgraded his rating for the San Diego-based firm to Outperform from Neutral and increased the share price target to $55 from $48.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: methylation patterns in multiple myeloma, recent Y chromosome bottleneck, and more.

By studying the spectra of microbes on Earth, a team of researchers hopes to be better equipped to detect any on other worlds.

SolveBio's Mark Kaganovich says at TechCrunch that genomics needs an app to push it into the mainstream.

A University of Michigan team is using a Facebook app to recruit and keep in touch with participants in its 'Genes for Good' project.

Apr
15
Sponsored by
WaferGen

This live online seminar will highlight recent trends in applying next-generation sequencing in the clinical setting, with a particular focus on oncology and rare disease.